Clinical trial
Monoclonal Antibody Therapy With Sargramostim and Interleukin-2 in Treating…
NCT00005576 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00005576 |
|---|---|
| Title | Monoclonal Antibody Therapy With Sargramostim and Interleukin-2 in Treating Children With Neuroblastoma |
| Official title | A PHASE I STUDY OF CHIMERIC HUMAN/MURINE ANTI-GD2 MONOCLONAL ANTIBODY (ch14.18) WITH GM-CSF AND INTERLEUKIN-2 (IL-2) IN CHILDREN WITH NEUROBLASTOMA IMMEDIATELY POST AUTOLOGOUS BMT OR PBSC RESCUE |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Disseminated Neuroblastoma, Recurrent Neuroblastoma, Regional Neuroblastoma |
| Intervention type | Biological, Drug |
| Interventions | monoclonal antibody Ch14.18, isotretinoin, aldesleukin, sargramostim |
| Enrollment | 6 |
| Start date | Jan 1, 2001 |
| Primary completion | Mar 1, 2002 |
| First posted | Nov 5, 2003 |
| Last update posted | Jan 16, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: